Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 40,761 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 40,761 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $0.65, for a total value of $26,494.65. Following the sale, the director directly owned 2,413,158 shares of the company’s stock, valued at $1,568,552.70. This represents a 1.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Luke Evnin also recently made the following trade(s):

• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $7,625.60.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total transaction of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $40,921.83.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL traded down $0.00 during midday trading on Wednesday, reaching $0.64. 208,688 shares of the company were exchanged, compared to its average volume of 310,372. The stock has a market cap of $31.13 million, a PE ratio of -0.40 and a beta of 0.77. The business’s fifty day moving average is $0.94 and its two-hundred day moving average is $1.26. Werewolf Therapeutics, Inc. has a one year low of $0.56 and a one year high of $2.38. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

HOWL has been the subject of a number of research analyst reports. HC Wainwright decreased their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 19th. Bank of America decreased their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently made changes to their positions in the stock. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter valued at approximately $28,000. Qube Research & Technologies Ltd acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $48,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the 1st quarter worth $79,000. Y Intercept Hong Kong Ltd purchased a new position in Werewolf Therapeutics in the 2nd quarter worth $92,000. Finally, Susquehanna International Group LLP lifted its position in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.